Last reviewed · How we verify
Percutaneous coronary intervention
Approved treatments
- Argatroban · Hikma Pharm Co Ltd
Argatroban works by directly inhibiting the activity of thrombin, a key enzyme in the blood clotting process. - Kengreal · Chiesi
Kengreal blocks the action of ADP on platelets, preventing platelet activation and aggregation. - Angiomax · Novartis
Bivalirudin directly inhibits thrombin by binding to its catalytic site and anion-binding exosite, preventing thrombus formation. - Iopidine · Harrow Health
- Brilinta · AstraZeneca
- Aggrastat · Medicure
Aggrastat works by blocking the integrin alpha-IIb/beta-3 receptor on platelets, preventing them from aggregating and forming blood clots. - Brilinta · AstraZeneca
- Integrilin · Merck & Co.
Integrilin blocks the binding of fibrinogen to platelets, preventing them from clumping together and forming clots. - Effient · Cosette
Effient works by blocking the P2Y12 receptor on platelets, preventing them from aggregating and forming blood clots. - Reopro · Johnson & Johnson
- integrilin · University of Cincinnati
- Ticlid
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Percutaneous coronary intervention patent landscape — cliff calendar, originator estates, attackable patents
- Percutaneous coronary intervention treatment landscape brief
- Percutaneous coronary intervention treatment updates RSS
Frequently asked questions about Percutaneous coronary intervention
What drugs treat Percutaneous coronary intervention?
Tracked treatments include Argatroban, Kengreal, Angiomax, Iopidine, Brilinta, Aggrastat, Integrilin, Effient.
What is the treatment for Percutaneous coronary intervention?
Standard treatment for Percutaneous coronary intervention includes Argatroban, Kengreal, Angiomax, Iopidine, Brilinta. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Percutaneous coronary intervention patent cliff · Percutaneous coronary intervention CI report
- Treatment: Argatroban · Hikma Pharm Co Ltd
- Treatment: Kengreal · Chiesi
- Treatment: Angiomax · Novartis
- Treatment: Iopidine · Harrow Health
- Treatment: Brilinta · AstraZeneca
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing